Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
Technology
Health & Fitness
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/db/ac/ab/dbacab58-d6ba-b5f6-0718-48f495486937/mza_18314426264324614457.jpg/600x600bb.jpg
Talking Urology Podcast
Talking Urology
115 episodes
6 months ago
Damien Bolton & Andrew Weickhardt discuss ‘The COVID conundrum: loss and lessons learned.
Show more...
Health & Fitness
RSS
All content for Talking Urology Podcast is the property of Talking Urology and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Damien Bolton & Andrew Weickhardt discuss ‘The COVID conundrum: loss and lessons learned.
Show more...
Health & Fitness
https://i1.sndcdn.com/artworks-000598870787-9g49v7-t3000x3000.jpg
ANZUP 2019 Interviews - Andrew Weickhardt talks with Ian Davis about the ENZAMET study
Talking Urology Podcast
13 minutes 10 seconds
6 years ago
ANZUP 2019 Interviews - Andrew Weickhardt talks with Ian Davis about the ENZAMET study
In this ANZUP conference highlight, Andrew Weickhardt chats with Australia’s very own Ian Davis about ANZUP’s successful world leading phase 3 study, ENZAMET. Ian outlines ENZAMET for men with newly diagnosed metastatic hormone naïve prostate cancer and how it differs from the other trials involving second line anti-androgens in this space. Ian also discusses how you might decide between the myriad of treatment options that have now shown effect in the upfront hormone naïve metastatic setting.
Talking Urology Podcast
Damien Bolton & Andrew Weickhardt discuss ‘The COVID conundrum: loss and lessons learned.